LRTI Flashcards

(47 cards)

1
Q

Lower respiratory tract

A

Starts at the trachea–>bronchi–>bronchioles–>alveoli

Alveoli–>site of gas exchange where pneumonia occurs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Nasopharynx

A

Nasal hair–>net captures pathogens
IgA secretion–>binds to pathogens
Fibronectin–>binds to pathogens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Oropharynx

A

Saliva–>form that can remove bacteria or transfer

Slough epithelial cells–>gets rid of attached bacteria to collect in saliva

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Trachea/bronchi

A

Cough
Mucociliary apparatus (cilia)
Epiglottic reflux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Alveoli

A

Alveolar lining fluid–>reduce binding to pathogens
Macrophages + PMN–>innate immunity
Cell-mediated immunity–>T and B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pathogen-mediated

A

Surface adhesions–>grab the cell
Pili–>grab the cell
Exotoxins–>fight immune cells
Enzymes–>fight immune cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Host interventions

A

Smoking–>decreased mucociliary apparatus
Alcohol
Altered consciousness
Endotracheal tubes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Host-disease States

A

Immunosuppression
Diabetes
Asplenia–>decreased immune system
Elderly–>decreased immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is community-acquired pneumonia?

A

Pneumonia that developed outside of the hospital or within 48 hours of hospital admission

Most common infection-related hospitalization and mortality in the US

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pathogenesis of CAP

A

Aspiration–>most common with bacterial
- occurs during healthy individuals and sleep
- organisms are usually cleared if host defenses functioning properly

Aerosolization–>most common with bacterial
- direct inhalation of pathogen in droplet nuclei form

Bloodborne

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Streptococcus pneumoniae (gram +)

A

Prevalence: asplenia, immunocompromised, chemo

Resistance: penicillin, macrolide
- Age < 6 or > 65
- Prior antibiotics
- Recent hospitalization
- Close quarters
- Co-morbid conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Haemophilus influenzae

A

gram (-)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Legionella pneumophila–> atypical

A

Spread: aerosolization
Risk: older males, chronic bronchitis, smokers, immunocompromised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Chlamydia pneumoniae

A

atypical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mycoplasma pneumoniae–> atypical

A

Spread: person-to-person contact

2-3 week incubation period followed by slow onset of symptoms
- persistant, non-productive cough–> “walking pneumonia”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Staphylococcus aureus

A

Prevalence: very low

Risk factors for MRSA
- 2-14 days post influenza
- Previous MRSA infection
- Previous hospitalization
- Previous IV antibiotic

Predictive values: 95-99% negative, 56.8% positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Classic presentation

A

Sudden onset

Fever, chills, pleuritic chest pain, SOB, productive cough

Gradual onset with mycoplasma and chlamydia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Elderly presentation

A

May be absent

Decreased functional status, weakness, mental status changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Vitals

A

Febrile: < 38 C
Tachycardia: HR > 90
Hypotensive: SBP < 90
Tachypnea: RR > 20

20
Q

Labs

A

WBC–>leukocytosis
SCr (elevated), BUN (elevated), LFTs
Low pulse oximetry
Nasopharyngeal PCR swab–> MRSA, viral
Urinary antigen tests–> strep pneumo, legionella

21
Q

Major criteria for severe CAP

A

Need 1

Septic shock requiring vasopressors

Respiratory failure required mechanical ventilation

22
Q

Minor criteria for severe CAP

A

Need 3

RR > 30
BUN > 20
WBC < 4,000
Plt < 100,000
T < 36 C
SBP < 90
Multilobe infiltrates
Confusion/disorientation

23
Q

Diagnosis

A

Chest radiography: Recommended for all patients for CAP
- Dense lobar consolidation/infiltrates = bacterial origin
- Patchy, diffuse, interstitial infiltrates = atypical or viral

Sputum: Color, amount, consistency, odor

Procalcitonin: Biomarker specifically for bacterial
- Dictates duration, not antibiotics

Blood culture–>only used in severe

Respiratory culture–>only used in severe
- Negative in 40-50% in patients with CAP

24
Q

Supportive treatment

A

Humidified O2
Bronchodilators
Fluids
Chest physiotherapy

25
Empiric therapy-->OUTPATIENT Healthy, no comorbidities/risk factors
Minimum of 5 total days Amoxicillin 1 g PO q8h Doxycycline 100 mg PO BID Azithromycin (z-pak)-->ONLY IF MACROLIDES RESISTANCE < 25%
26
Empiric therapy-->OUTPATIENT Healthy, comorbidities/risk factors
Heart, lung, renal, DM, alcoholism, malignancy, immunosuppression Respiratory FQ (Levofloxacin or Moxifloxacin) Beta-lactam + macrolide/doxycycline-->preferred - Augmentin - Cefuroxime - Cefpodoxime
27
Empiric therapy--> INPATIENT Non-severe: no MRSA/P, aeruginosa risk factors
Respiratory FQ (Levofloxacin or Moxifloxacin) Beta-lactam + macrolide/doxycycline-->preferred - Unasyn - Ceftriaxone
28
Empiric therapy-->INPATIENT Severe CAP: no MRSA/P. aeruginosa risk factors
Respiratory FQ + Beta-lactam Beta-lactam + macrolide/doxycycline-->preferred - Unasyn - Ceftriaxone
29
If patient has MRSA risk factors
Above agents + vancomycin/linezolid
30
P. aeruginosa risk factors
Previous isolated infection, previous hospitalization in 90 days Above agents + Zosyn/cefepime/meropenem
31
ONLY USE STEROIDS IF CAP + SEPTIC SHOCK
32
What is HAP/VAP?
HAP: pneumonia occurring > 48 hours after hospital admission VAP: pneumonia occurring > 48 hours after endotracheal intubation
33
Pathogenesis of HAP/VAP
Micro-aspiration of oropharnygenal secretions that colonized with bacteria - Gram (+) colonization-->3-5 days-->gram (-) organism Aspiration Direct inoculation Hematogenous
34
Common pathogens of HAP/VAP
Gram (-): P. aeruginosa, enterbacteriales, acinetobacter Gram (+): Staphylococcus aureus
35
Risk factors for HAP/VAP
Age Duration of hospitalization Endotracheal intubation Nasogastric tube Surgery Previous antibiotic therapy Severity of comorbid disease Altered mental status
36
Risk factors for MDR HAP
Prior IV antibiotic use within 90 days
37
Risk factors for MRSA HAP/VAP
Prior IV antibiotic use within 90 days
38
Risk factors for P. aeruginosa MDR
Prior IV antibiotic use within 90 days
39
Risk factors for MDR VAP
Prior IV antibiotic use within 90 days Septic shock at time of diagnosis Acute respiratory distress syndrome prior to diagnosis Acute renal replacement therapy prior to diagnosis > 5 days hospitalization prior to diagnosis
40
Microbiology Testing
Respiratory cultures-->recommended for all patients -Noninvasive> invasive - If invasive--> BAL > 10 ^4-->diagnosis
41
Diagnosis for HAP/VAP
no gold standard Timing--> 48 hours from admission Presentation-->clinical signs + new ling infiltrates
42
HAP-->low risk for mortality (no septic shock or ventilation)
Goal: MSSA + P. aeruginosa Zosyn, Cefepime, Meropenem, Imipenem, Levofloxacin
43
HAP-->low risk for mortality (no septic shock or ventilation) + MRSA
Zosyn, Cefepime, Meropenem, Imipenem, Levofloxacin + Vancomycin/Linezolid
44
HAP-->high risk for mortality (septic shock or ventilation) + MRSA
Goal: MRSA + P. aeruginosa 2 of the following (1 b-lactam + 1 non-b-lactam) Zosyn, Cefepime, Meropenem, Imipenem, Levofloxacin, Tobramycin/Amikacin+ Vancomycin/Linezolid
45
VAP
Goal: MRSA + P. aeruginosa Zosyn, Cefepime, Meropenem, Imipenem, Levofloxacin, Tobramycin/Amikacin+ Vancomycin/Linezolid
46
Non-beta-lactam considerations
Daptomycin-->never use for LRTI Aminoglycosides-->recommend against monotherapy Polymyxins-->reserved for pts with high prevalence of MDR Tigecycline-->good for polymicrobial infections
47
Duration for HAP/VAP
7 days if clinically stable